Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8657 - 8664 of 12086 results
Latest OCR Enforcement Action: Underbed Storage is Not Appropriate for PHI
February 5, 2016| Blog| Viewpoint
Court in BP Oil Spill Litigation Denies Standing for Special Purpose Entities Created Solely for Litigation
February 4, 2016| Blog| Viewpoint
The Health and Welfare "Wrap" Document: What It Is and Why You Want One (Employment Matters)
February 4, 2016| Blog| Viewpoint
FDA Places Ban on Import of GE Salmon
February 4, 2016| Blog| Viewpoint
Behind the Curtain: Shkreli was NOT the Big Story on the Hill Today
February 4, 2016| Blog| Viewpoint
A Preview of Business Immigration in 2016: H-1Bs (Part 1/6)
February 4, 2016| Blog| Viewpoint
Energy Bill the Focus of Congressional Debate
February 3, 2016| Blog| Viewpoint
Telemedicine Momentum Picking up Steam as New Legislation Introduced in U.S. Senate
February 3, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|